ホーム › 前立腺がん › バージニア › Charlottesville
Charlottesville、VAにおける前立腺がんの臨床試験
Charlottesvilleとその周辺地域（約30マイル以内）の拠点で、前立腺がんに関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
被験者募集中第3相
- University of Virginia Health System ( Site 0054), Charlottesville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
被験者募集中第3相
- University of Virginia Comprehensive Cancer Center, Charlottesville
- University of Virginia, Charlottesville
- UVA Health Cancer Care Pantops, Charlottesville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
被験者募集中第3相
- University of Virginia Cancer Center, Charlottesville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
被験者募集中第2相
- University of Virginia Cancer Center, Charlottesville
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Sentara Martha Jefferson Hospital, Charlottesville
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
被験者募集中第3相
- University of Virginia Cancer Center, Charlottesville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
被験者募集中第2相
- University of Virginia Comprehensive Cancer Center, Charlottesville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Virginia, Charlottesville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
被験者募集中第3相
- University of Virginia Cancer Center, Charlottesville
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
被験者募集中第1/2相
- University of Virginia, Charlottesville
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
被験者募集中
- University of Virginia Health System, Charlottesville
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
被験者募集中観察研究
- University of Virginia, Charlottesville
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
被験者募集中
- University of Virginia, Charlottesville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
被験者募集中第1相
- University of Virginia Cancer Center, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Charlottesville
他の都市における前立腺がんの試験
- New York City, NY103件の研究
- Houston, TX76件の研究
- Los Angeles, CA61件の研究
- Boston, MA59件の研究
- St. Louis, MO46件の研究
- Chicago, IL45件の研究
- San Francisco, CA45件の研究
- Philadelphia, PA44件の研究
- Baltimore, MD43件の研究
- Nashville, TN42件の研究
- Seattle, WA42件の研究
- Washington, DC38件の研究
Charlottesvilleにおける他の研究
- 非小細胞肺癌21件の研究
- 急性骨髄性白血病16件の研究
- 転移性癌13件の研究
- 子宮内膜がん13件の研究
- がん（全種類）13件の研究
- 肺がん13件の研究
- 心不全11件の研究
- 卵巣がん10件の研究
- 大腸癌10件の研究
- 1型糖尿病9件の研究
- 乳がん9件の研究
- 膵臓がん9件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。